Idebenone Acts against Growth of Helicobacter pylori by Inhibiting Its Respiration

ABSTRACT Growth of Helicobacter pylori was inhibited by the quinones, idebenone, duroquinone, menadione, juglone, and coenzyme Q1 at low concentrations of 0.8 to 3.2 μg/ml. Idebenone specifically inhibited H. pylori growth by inhibiting respiration and decreasing the cellular ATP level. The respiratory inhibition was accompanied by reduction of idebenone by the H. pylori cells.

[1]  P. Rustin,et al.  Quinone analogues regulate mitochondrial substrate competitive oxidation. , 2004, Biochemical and biophysical research communications.

[2]  Robert J. Maier,et al.  An NADPH Quinone Reductase of Helicobacter pylori Plays an Important Role in Oxidative Stress Resistance and Host Colonization , 2004, Infection and Immunity.

[3]  M. Fujino,et al.  L-Serine, D- and L-proline and alanine as respiratory substrates of Helicobacter pylori: correlation between in vitro and in vivo amino acid levels. , 2003, Microbiology.

[4]  K. Murakami,et al.  Eradication rates of clarithromycin‐resistant Helicobacter pylori using either rabeprazole or lansoprazole plus amoxicillin and clarithromycin , 2002, Alimentary pharmacology & therapeutics.

[5]  R. P. Blankfield,et al.  Helicobacter pylori infection and the development of gastric cancer. , 2001, The New England journal of medicine.

[6]  K. Nagata,et al.  Inhibitory Activities of Lansoprazole against Respiration in Helicobacter pylori , 2001, Antimicrobial Agents and Chemotherapy.

[7]  A. Munnich,et al.  Effect of idebenone on cardiomyopathy in Friedreich's ataxia: a preliminary study , 1999, The Lancet.

[8]  R. Poole,et al.  Microbial ubiquinones: multiple roles in respiration, gene regulation and oxidative stress management. , 1999, Microbiology.

[9]  J. Christodoulou,et al.  Respiratory chain complex III deficiency with pruritus: A novel vitamin responsive clinical feature , 1999 .

[10]  J. Christodoulou,et al.  Respiratory chain complex III [correction of complex] in deficiency with pruritus: a novel vitamin responsive clinical feature. , 1999, The Journal of pediatrics.

[11]  J. Koyama,et al.  Antimicrobial Activity of Novel Furanonaphthoquinone Analogs , 1998, Antimicrobial Agents and Chemotherapy.

[12]  R. Poole,et al.  The respiratory chain of Helicobacter pylori: identification of cytochromes and the effects of oxygen on cytochrome and menaquinone levels. , 1996, FEMS microbiology letters.

[13]  P. Benefield,et al.  Idebenone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in age-related cognitive disorders. , 1994, Drugs & aging.

[14]  B. Burns,et al.  Glucose utilization and lactate production by Helicobacter pylori. , 1993, Journal of general microbiology.

[15]  G. Mendz,et al.  Glucose phosphorylation in Helicobacter pylori. , 1993, Archives of biochemistry and biophysics.

[16]  P D Klein,et al.  Effect of Treatment of Helicobacter pylori Infection on the Long-term Recurrence of Gastric or Duodenal Ulcer , 1992, Annals of Internal Medicine.

[17]  G. Friedman,et al.  Helicobacter pylori infection and the risk of gastric carcinoma. , 1991, The New England journal of medicine.

[18]  I. Zs.-Nagy.  Chemistry, toxicology, pharmacology and pharmacokinetics of idebenone: a review. , 1990 .

[19]  M. Blaser.  Helicobacter pylori and the pathogenesis of gastroduodenal inflammation. , 1990, The Journal of infectious diseases.

[20]  C. W. Moss,et al.  Isoprenoid quinones of Campylobacter cryaerophila, C. cinaedi, C. fennelliae, C. hyointestinalis, C. pylori, and "C. upsaliensis" , 1990, Journal of clinical microbiology.

[21]  I. Zs -Nagy.  Chemistry, toxicology, pharmacology and pharmacokinetics of idebenone: a review. , 1990, Archives of gerontology and geriatrics.

[22]  C. Mcnulty,et al.  Rapid identification of Campylobacter pylori (C. pyloridis) by preformed enzymes , 1987, Journal of clinical microbiology.